Sainz Bruno, Rausch Joshua M, Gallaher William R, Garry Robert F, Wimley William C
Department of Microbiology and Immunology, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-43, New Orleans, LA 70112, USA.
J Virol. 2005 Jun;79(11):7195-206. doi: 10.1128/JVI.79.11.7195-7206.2005.
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a newly identified member of the family Coronaviridae and poses a serious public health threat. Recent studies indicated that the SARS-CoV viral spike glycoprotein is a class I viral fusion protein. A fusion peptide present at the N-terminal region of class I viral fusion proteins is believed to initiate viral and cell membrane interactions and subsequent fusion. Although the SARS-CoV fusion protein heptad repeats have been well characterized, the fusion peptide has yet to be identified. Based on the conserved features of known viral fusion peptides and using Wimley and White interfacial hydrophobicity plots, we have identified two putative fusion peptides (SARS(WW-I) and SARS(WW-II)) at the N terminus of the SARS-CoV S2 subunit. Both peptides are hydrophobic and rich in alanine, glycine, and/or phenylalanine residues and contain a canonical fusion tripeptide along with a central proline residue. Only the SARS(WW-I) peptide strongly partitioned into the membranes of large unilamellar vesicles (LUV), adopting a beta-sheet structure. Likewise, only SARS(WW-I) induced the fusion of LUV and caused membrane leakage of vesicle contents at peptide/lipid ratios of 1:50 and 1:100, respectively. The activity of this synthetic peptide appeared to be dependent on its amino acid (aa) sequence, as scrambling the peptide rendered it unable to partition into LUV, assume a defined secondary structure, or induce both fusion and leakage of LUV. Based on the activity of SARS(WW-I), we propose that the hydrophobic stretch of 19 aa corresponding to residues 770 to 788 is a fusion peptide of the SARS-CoV S2 subunit.
严重急性呼吸综合征相关冠状病毒(SARS-CoV)是冠状病毒科新发现的成员,对公众健康构成严重威胁。最近的研究表明,SARS-CoV病毒刺突糖蛋白是一种I类病毒融合蛋白。I类病毒融合蛋白N端区域存在的融合肽被认为可启动病毒与细胞膜的相互作用及随后的融合过程。尽管SARS-CoV融合蛋白的七肽重复序列已得到充分表征,但融合肽尚未被鉴定出来。基于已知病毒融合肽的保守特征并使用Wimley和White界面疏水性图谱,我们在SARS-CoV S2亚基的N端鉴定出两个假定的融合肽(SARS(WW-I)和SARS(WW-II))。这两个肽均具有疏水性,富含丙氨酸、甘氨酸和/或苯丙氨酸残基,并包含一个典型的融合三肽以及一个中心脯氨酸残基。只有SARS(WW-I)肽能强烈地分配到大单层囊泡(LUV)膜中,形成β-折叠结构。同样,只有SARS(WW-I)在肽/脂质比分别为1:50和1:100时诱导LUV融合并导致囊泡内容物的膜泄漏。这种合成肽的活性似乎取决于其氨基酸(aa)序列,因为打乱肽序列会使其无法分配到LUV中,无法呈现特定的二级结构,也无法诱导LUV融合和泄漏。基于SARS(WW-I)的活性,我们提出对应于770至788位残基的19个aa的疏水片段是SARS-CoV S2亚基的融合肽。